Service de pédiatrie multidisciplinaire, Hôpital de la Timone, Marseille, France.
Service médico-chirurgical de cardiologie pédiatrique et congénitale, Hôpital de la Timone, Marseille, France.
Orphanet J Rare Dis. 2021 Aug 17;16(1):364. doi: 10.1186/s13023-021-01987-y.
Transplantation is a saving therapeutic that has heavy consequences. The quality of life (QoL) of transplanted children and their parents has been little studied and should help physicians better manage these patients. The objectives of the study were to assess: (1) the QoL of transplanted children and parents and compare it with that of children with other chronic conditions associated with long-term consequences, and (2) potential variables modulating the QoL.
This cross-sectional study was performed in a multidisciplinary paediatric unit (Timone Hospital, Marseille, France). Children were less than 18 years old; had a liver, kidney or heart transplant; and had a time since transplantation of 1-10 years. Socio-demographics and clinical data were recorded from medical forms. The QoL was assessed using the VSP-A (Vécu et Santé Perçue de l'Adolescent et de l'Enfant) and the WhoQoL self-reported questionnaires.
Forty-five families were included (response rate: 76%). The transplanted organs were the liver for 20 children, the kidney for 15 children, and the heart for 10 children. The QoL of transplanted children reported by their parents was better than that of children with inborn errors of metabolism and similar to that of childhood leukaemia survivors. The QoL of parents of transplanted children was better than that of parents of children with inborn errors of metabolism and did not differ from French norms. The QoL did not differ according to the nature of the transplanted organ, sex or the main sociodemographic data. The main modulators decreasing QoL were residual treatment level, medications switch and the presence of another regular treatment.
Transplanted children and their families reported a fairly preserved QoL compared to children with other chronic health conditions. Special attention should be given to QoL modulators related to therapeutic management (medication switches, regular treatments) that might be amenable to improve the QoL. Trial registration Ethics committee of Aix-Marseille University, France (reference number: 2014-08-04-03, 24/4/2015; https://www.univ-amu.fr/fr/public/comite-dethique ).
移植是一种具有重大影响的挽救性治疗。接受移植的儿童及其父母的生活质量(QoL)很少被研究,而这有助于医生更好地管理这些患者。本研究的目的是评估:(1)接受移植的儿童及其父母的 QoL,并与患有其他与长期后果相关的慢性疾病的儿童进行比较;(2)可能影响 QoL 的变量。
这是一项在法国马赛蒂姆诺医院的多学科儿科病房进行的横断面研究。研究对象为年龄小于 18 岁;接受过肝、肾或心脏移植;且移植后时间为 1-10 年的儿童。社会人口统计学和临床数据从病历中记录。使用 VSP-A(青少年和儿童感知的生活和健康)和 Wh oQoL 自我报告问卷评估 QoL。
共纳入 45 个家庭(应答率:76%)。移植的器官包括 20 例儿童的肝脏、15 例儿童的肾脏和 10 例儿童的心脏。父母报告的接受移植的儿童的 QoL 优于患有先天性代谢错误的儿童,与儿童白血病幸存者相似。接受移植的儿童的父母的 QoL 优于患有先天性代谢错误的儿童的父母,与法国常模无差异。QoL 与移植器官的性质、性别或主要社会人口统计学数据无关。降低 QoL 的主要调节剂是残留治疗水平、药物转换和存在其他常规治疗。
与患有其他慢性健康状况的儿童相比,接受移植的儿童及其家庭报告的 QoL 相当保留。应特别关注与治疗管理(药物转换、常规治疗)相关的 QoL 调节剂,这些调节剂可能可以改善 QoL。
法国艾克斯马赛大学伦理委员会,编号:2014-08-04-03,2015 年 4 月 24 日;https://www.univ-amu.fr/fr/public/comite-dethique。